GABP-beta1L: A therapeutic target for treatment of teratose-mutation-related cancers.

Researchers at the University of California, San Francisco, found that GABP-beta1L, a specific component of gabP protein, is the key to uncontrolled division and reproduction of glioblastoma cells associated with telomerase reverse transcriptase (TERT) promoter mutations.
their paper published in the journal Tumor Cells on Monday, they said the new findings offer a promising drug target for future treatment of glioblastoma and many other cancers associated with TERT promoter mutations.
longer than healthy cells and is one of the most important characteristics of tumor cells, and their number of divisions is not strictly limited like healthy cells, so they can continue to divide and spread.
scientists believe this ability of tumor cells may be related to the TERT promoter mutation.
TERT promoter mutation is one of the three most common mutations in all human cancers and the most common in glioblastoma, a deadly brain cancer.
recent research has shown that more than 50 types of cancer are caused by TERT promoter mutations.
also studies have shown that these mutations bind THE transcription factor of GABP to the TERT promoter and activate it, but in healthy cells GABP and TERT are usually independent of each other.
, researchers at the University of California, San Francisco, found that glioblastoma patients with TERT-initiator mutations had tumor cells in their bodies dependent on GABP proteins to survive.
this protein is critical to the functioning of most cells, one of these specific components, GABP-beta1L, does not appear to be necessary in normal cells.
when researchers removed GABP-beta1L from lab-cultured glioblastoma cells, including through CRISPR gene editing, tumor cells slowed down significantly.
subsequent mouse experiments showed that unedited glioblastoma cells from human patients grew rapidly after implantation in mice and quickly led to death in mice, while tumor cells that were genetically edited without GABP-beta1L grew slowly and were less lethal in mice.
researchers point out that GABP-beta1L is a promising new drug target for the treatment of glioblastoma and many other cancers associated with TERT initiator mutations.
they will look for small molecule drugs that have a similar effect to the gene-editing techniques used in the experiment to promote the treatment of related cancers.
.